ReviewCurrent opinion in biotechnology2021
Phage engineering and the evolutionary arms race.
Review in Current opinion in biotechnology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 49 citations in OpenAlex.
- A Comprehensive Review: Exploring the Potential of Bacteriophages in Agriculture and Environment.Current microbiology · 2025Review
- Real-TimeACS biomaterials science & engineering · 2025Article
- Engineering bacteriophages for targeted superbug eradication.Molecular biology reports · 2025Review
- EngineeredFrontiers in microbiology · 2025Article
- Article
- Beyond Antibiotics: Exploring the Potential of Bacteriophages and Phage Therapy.PHAGE (New Rochelle, N.Y.) · 2024Review
- Nanomechanical resilience and thermal stability of RSJ2 phage.Scientific reports · 2024Article
- Phage-based delivery systems: engineering, applications, and challenges in nanomedicines.Journal of nanobiotechnology · 2024Review
- Improving phage therapy by evasion of phage resistance mechanisms.JAC-antimicrobial resistance · 2024Review
- Designing molecules: directing stem cell differentiation.Frontiers in bioengineering and biotechnology · 2024Review
- A modular phage vector platform for targeted photodynamic therapy of Gram-negative bacterial pathogens.iScience · 2023Article
- The Biotechnological Application of Bacteriophages: What to Do and Where to Go in the Middle of the Post-Antibiotic Era.Microorganisms · 2023Review
- Genetically engineered filamentous phage for bacterial detection using magnetic resonance imaging.Sensors & diagnostics · 2023Article
- Beyond the Risk of Biofilms: An Up-and-Coming Battleground of Bacterial Life and Potential Antibiofilm Agents.Life (Basel, Switzerland) · 2023Review
- Disarm The Bacteria: What Temperate Phages Can Do.Current issues in molecular biology · 2023Review
- Engineering bacteriophages for enhanced host range and efficacy: insights from bacteriophage-bacteria interactions.Frontiers in microbiology · 2023Review
- Advance on Engineering of Bacteriophages by Synthetic Biology.Infection and drug resistance · 2023Review
- Hijacking the self-replicating machine of bacteriophage for PCR-based cascade signal amplification in detecting SARS-CoV-2 viral marker protein in serum.Sensors and actuators. B, Chemical · 2023Article
- Recent Advances in Phage-Based Therapeutics for Multi-Drug ResistantBioengineering (Basel, Switzerland) · 2022Review
- Bacteriophage T4 as a nanovehicle for delivery of genes and therapeutics into human cells.Current opinion in virology · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
Phages are versatile agents for delivering a variety of cargo, including nanomaterials, nucleic acids, and small molecules. A potentially important application is treatment of antibiotic-resistant infections. All of these applications require molecular engineering of the phages, including chemical modification and genetic engineering. Phages are remarkably amenable to such engineering. We review some examples, including for controlled phage therapy. We suggest that the ability of phages to support extensive engineering may have evolutionary origins in the billions-year-old 'arms race' between bacteria and phages, which selects for sequences and structures that are robust in the face of rapid evolutionary change. This leads to high tolerance of both naturally evolved mutations and synthetic molecular engineering.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.